Temporal trends over 3 decades and intrafamilial clustering of HPV types in Swedish patients with cervical cancer in situ

International Journal of Cancer

Volumn 125, Issue 12, 2009, Pages 2930-2935

  Ivansson, Emma L ^a   Gustavsson, Inger M ^a   Wilander, Erik ^a,b   Magnusson, Patrik K E ^c   Gyllensten, Ulf B ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Archived tissue; Cervical cancer; HPV; Multi case families; Real time PCR

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGED; ARTICLE; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; GENETIC SUSCEPTIBILITY; HEALTH PROGRAM; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SWEDEN; UTERINE CERVIX CANCER; WART VIRUS;

ADOLESCENT; ADULT; AGED; CARCINOMA IN SITU; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; SWEDEN; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 72449163681     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24631     Document Type: Article

References (28)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543
2. Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002;325:572. (Pubitemid 35026129)
3. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, Hallmans G, Dillner J. Type-specific persistence of human papillo-mavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-1638
4. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-1255
5. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-278
6. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-2170 (Pubitemid 46977438)
7. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927 (Pubitemid 46740302)
8. Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008;26 (Suppl 10):K53-61.
9. Stanley M, Lowy DR, Frazer I. Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006;24 (Suppl 3):S106-13. (Pubitemid 44293025)
10. Bertelsen BI, Kugarajh K, Skar R, Laerum OD. HPV subtypes in cervical cancer biopsies between 1930 and 2004: detection using general primer pair PCR and sequencing. Virchows Arch 2006;449:141-147
11. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527 (Pubitemid 36159887)
12. Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, Desai M, Mather J, Moss S, Roberts C, Kitchener HC. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer 2008;98:1704-1709 (Pubitemid 351684674)
13. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009;101:475-487
14. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428 (Pubitemid 28135669)
15. Magnusson PK, Sparen P, Gyllensten UB. Genetic link to cervical tumours. Nature 1999;400:29-30.
16. Engelmark M, Beskow A, Magnusson J, Erlich H, Gyllensten U. Affected sib-pair analysis of the contribution of HLA class I and class II loci to development of cervical cancer. Hum Mol Genet 2004;13:1951-1958 (Pubitemid 39214342)
17. Beskow AH, Ronnholm J, Magnusson PK, Gyllensten UB. Susceptibility locus for epidermodysplasia verruciformis not linked to cervical cancer in situ. Hereditas 2001;135:61-63 (Pubitemid 34411187)
18. Josefsson AMP, Gyllensten UB. Human papillomavirus detection by PCR and typing by dot-blot. In: Rosanna P, Sparling PF. Methods in molecular medicine. Sexually transmitted diseases: methods and protocols. Totowa, NJ: Humana Press, 1998. 171-193
19. Moberg M, Gustavsson I, Gyllensten U. Real-time PCR-based system for simultaneous quantification of human papillomavirus types associated with high risk of cervical cancer. J Clin Microbiol 2003;41: 3221-3228 (Pubitemid 36842325)
20. Roberts CC, Tadesse AS, Sands J, Halvorsen T, Schofield TL, Dalen A, Skjeldestad FE, Jansen KU. Detection of HPV in Norwegian cervical biopsy specimens with type-specific PCR and reverse line blot assays. J Clin Virol 2006;36:277-282 (Pubitemid 44088487)
21. Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 2008;123:1864-1870
22. Bergstrom R, Sparen P, Adami HO. Trends in cancer of the cervix uteri in Sweden after cytological screening. Br J Cancer 1999;81:159-166 (Pubitemid 29415507)
23. Kitchener HC, Castle PE, Cox JT. Achievements and limitations of cervical cytology screening. Vaccine 2006;24 (Suppl 3):S3/63-70.
24. Kovacic MB, Castle PE, Herrero R, Schiffman M, Sherman ME, Wacholder S, Rodriguez AC, Hutchinson ML, Bratti MC, Hildesheim A, Morales J, Alfaro M, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 2006;66:10112-10119 (Pubitemid 44672065)
25. Jeronimo J, Massad LS, Schiffman M. Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. Am J Obstet Gynecol 2007;197:47 e1-8.
26. Ivansson EL, Magnusson JJ, Magnusson PK, Erlich HA, Gyllensten UB. MHC loci affecting cervical cancer risk: distinguishing the effects of HLA-DQB1 and non-HLA genes TNF, LTA, TAP1 and TAP2. Genes Immun 2008;9:613-623
27. Beskow AH, Josefsson AM, Gyllensten UB. HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. Int J Cancer 2001;93:817-822
28. Beskow AH, Moberg M, Gyllensten UB. HLA class II allele control of HPV load in carcinoma in situ of the cervix uteri. Int J Cancer 2005;117:510-514 (Pubitemid 41429577)